See the immunogenicity in infants and toddlers
Safety and effectiveness of MENVEO 1-vial presentation in children younger than 10 years have not been established.
Most infants and toddlers who completed the 4-dose series had a protective immune response with MENVEO 2-vial presentation1
- The primary endpoint for MENVEO 2-vial presentation (adequacy of immune response) was met following the full 4-dose series, given at 2, 4, 6, and 12 months of age*
- *Prespecified criteria for adequacy of immune response were met (lower limit of the 95% CI ≥80% for serogroup A and ≥85% for serogroups C, W, and Y).1
Geometric mean titers (GMTs) are a measure of the level of immune response to a vaccine in a specific study group. Infants and toddlers vaccinated with MENVEO 2-vial presentation were found to have circulating bactericidal antibodies to MenACWY following the full 4-dose series.